Brief: ImmunoPrecise Antibodies Successfully Engineers in silico Antibodies to Elusive Tumor Protein Using Its Patented LENSai Technology
19/08/2024 14:05
Aug 19 (Reuters) - Immunoprecise Antibodies Ltd IPA.O :
* IMMUNOPRECISE ANTIBODIES SUCCESSFULLY ENGINEERS IN SILICO
ANTIBODIES TO ELUSIVE TUMOR PROTEIN USING ITS PATENTED LENSAI
TECHNOLOGY
Source text for Eikon: ID:nBwb8x94ra
Further company coverage: IPA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Mindwalk Holdings
See all newsBrief: Mindwalk Holdings Corp. Announces Leadership Update
MindWalk Holdings Corp reports results for the quarter ended July 31 - Earnings Summary
Canada's MindWalk Q1 net loss widens on higher sales, marketing expenses
MindWalk Holdings Corp expected to post a loss of 8 cents a share - Earnings Preview
Brief: MindWalk Showcases Reefiq™ For Ai Drug Discovery At AMD Advancing Ai